Search Results - "ASSAD, Albert"

Adversarial synthesis learning enables segmentation without target modality ground truth by Huo, Yuankai, Xu, Zhoubing, Bao, Shunxing, Assad, Albert, Abramson, Richard G., Landman, Bennett A.

“…A lack of generalizability is one key limitation of deep learning based segmentation. Typically, one manually labels new training images when segmenting organs…”
Get full text

Splenomegaly Segmentation on Multi-Modal MRI Using Deep Convolutional Networks by Huo, Yuankai, Xu, Zhoubing, Bao, Shunxing, Bermudez, Camilo, Moon, Hyeonsoo, Parvathaneni, Prasanna, Moyo, Tamara K., Savona, Michael R., Assad, Albert, Abramson, Richard G., Landman, Bennett A.

“…The findings of splenomegaly, abnormal enlargement of the spleen, is a non-invasive clinical biomarker for liver and spleen diseases. Automated segmentation…”
Get full text

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results by Verstovsek, Srdan, Passamonti, Francesco, Rambaldi, Alessandro, Barosi, Giovanni, Rumi, Elisa, Gattoni, Elisabetta, Pieri, Lisa, Zhen, Huiling, Granier, Muriel, Assad, Albert, Cazzola, Mario, Kantarjian, Hagop M., Barbui, Tiziano, Vannucchi, Alessandro M.

Get full text

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis by Mascarenhas, John O, Talpaz, Moshe, Gupta, Vikas, Foltz, Lynda M, Savona, Michael R, Paquette, Ronald, Turner, A Robert, Coughlin, Paul, Winton, Elliott, Burn, Timothy C, O'Neill, Peter, Clark, Jason, Hunter, Deborah, Assad, Albert, Hoffman, Ronald, Verstovsek, Srdan

“…Combined Janus kinase 1 (JAK1) and JAK2 inhibition therapy effectively reduces splenomegaly and symptom burden related to myelofibrosis but is associated with…”
Get full text

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma by ANSELL, Stephen M, HORWITZ, Steven M, FISCHKOFF, Steven, ASSAD, Albert, BORCHMANN, Peter, ENGERT, Andreas, KHUDA DAD KHAN, LIN, Thomas, STRAIR, Roger, KELER, Tibor, GRAZIANO, Robert, BLANSET, Diann, YELLIN, Michael

“…MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models. To…”
Get full text

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS by Grunwald, Michael, Ritchie, Ellen, Rumi, Elisa, Assad, Albert, Hamer‐Maansson, J.E., Yu, Jingbo, Braunstein, Evan, Passamonti, Francesco

Get full text

Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis by Grunwald, Michael R., Ritchie, Ellen K., Rumi, Elisa, Assad, Albert, Hamer‐Maansson, J. E., Yu, Jingbo, Kalafut, Tricia, Braunstein, Evan, Passamonti, Francesco

“…Hydroxyurea is the preferred first‐line cytoreductive treatment for high‐risk essential thrombocythaemia (ET), but many patients are intolerant or refractory…”
Get full text

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer by Fogelman, David, Cubillo, Antonio, García‐Alfonso, Pilar, Mirón, María Luisa Limón, Nemunaitis, John, Flora, Daniel, Borg, Christophe, Mineur, Laurent, Vieitez, Jose M., Cohn, Allen, Saylors, Gene, Assad, Albert, Switzky, Julie, Zhou, Li, Bendell, Johanna

“…Background The Janus kinase/signal transducer and activator of transcription (JAK‐STAT) signaling pathway plays a key role in the systemic inflammatory…”
Get full text

In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma by CARDARELLI, Pina M, MOLDOVAN-LOOMIS, Maria-Cristina, ASSAD, Albert, WITTE, Alison, GRAZIANO, Robert F, KING, David J, PRESTON, Ben, BLACK, Amelia, PASSMORE, David, CHEN, Tseng-Hui, CHEN, Sharline, JIE LIU, KUHNE, Michelle R, SRINIVASAN, Mohan

“…Purpose: This study was undertaken to evaluate the effects of MDX-1401, a nonfucosylated fully human monoclonal antibody that binds to human CD30, and to…”
Get full text

SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth by Huo, Yuankai, Xu, Zhoubing, Moon, Hyeonsoo, Bao, Shunxing, Assad, Albert, Moyo, Tamara K., Savona, Michael R., Abramson, Richard G., Landman, Bennett A.

“…A key limitation of deep convolutional neural network (DCNN)-based image segmentation methods is the lack of generalizability. Manually traced training images…”
Get full text

Abstract CT253: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib by Yacoub, Abdulraheem, Stouffs, Michael, Zhou, Feng, Assad, Albert

“…Background: Ruxolitinib (JAK1/JAK2 inhibitor) is indicated for the treatment of adults with intermediate (INT) or high-risk myelofibrosis (MF), including…”
Get full text

Abstract CT252: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naïve Myelofibrosis by Yacoub, Abdulraheem, Erickson-Viitanen, Sue, Zhou, Feng, Assad, Albert

“…Background: Ruxolitinib (JAK1/JAK2 inhibitor) significantly improves outcomes in patients with myelofibrosis (MF); however, a subset of patients may experience…”
Get full text

A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis by Yacoub, Abdulraheem, Erickson-Viitanen, Susan, Zhou, Feng, Assad, Albert

“…Abstract only TPS7058 Background: Ruxolitinib (JAK1/JAK2 inhibitor) significantly improves outcomes in patients with myelofibrosis (MF); however, a subset of…”
Get full text

Targeting the PI3K pathway in myeloproliferative neoplasms by Gerds, Aaron T, Bartalucci, Niccolo, Assad, Albert, Yacoub, Abdulraheem

“…Decreasing efficacy over time and initial suboptimal response to Janus kinase (JAK) inhibitors such as ruxolitinib in a subset of patients are critical…”
Get full text

Robust Multicontrast MRI Spleen Segmentation for Splenomegaly Using Multi-Atlas Segmentation by Huo, Yuankai, Liu, Jiaqi, Xu, Zhoubing, Harrigan, Robert L., Assad, Albert, Abramson, Richard G., Landman, Bennett A.

“…Objective: Magnetic resonance imaging (MRI) is an essential imaging modality in noninvasive splenomegaly diagnosis. However, it is challenging to achieve…”
Get full text

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors by Beatty, Gregory L, Shahda, Safi, Beck, Thaddeus, Uppal, Nikhil, Cohen, Steven J, Donehower, Ross, Gabayan, Afshin Eli, Assad, Albert, Switzky, Julie, Zhen, Huiling, Von Hoff, Daniel D

“…Lessons Learned Itacitinib in combination with nab‐paclitaxel plus gemcitabine demonstrated an acceptable safety profile with clinical activity in patients…”
Get full text

POSTER: MPN-556 Treatment Comparison of Hydroxyurea vs Ruxolitinib in Essential Thrombocythemia (ET): A Matched Cohort Analysis by Grunwald, Michael R., Ritchie, Ellen, Rumi, Elisa, Assad, Albert, Hamer-Maansson, J.E., Yu, Jingbo, Braunstein, Evan, Passamonti, Francesco

Get full text

MPN-556 Treatment Comparison of Hydroxyurea vs Ruxolitinib in Essential Thrombocythemia (ET): A Matched Cohort Analysis by Grunwald, Michael R., Ritchie, Ellen, Rumi, Elisa, Assad, Albert, Hamer-Maansson, J.E., Yu, Jingbo, Braunstein, Evan, Passamonti, Francesco

“…Many high-risk ET patients are intolerant/refractory to hydroxyurea. Ruxolitinib improves ET symptoms; however, whether switching from hydroxyurea to…”
Get full text

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase by Tasian, Sarah K., Assad, Albert, Hunter, Deborah S, Du, Yining, Loh, Mignon L.

“…Background: Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype occurring in 15-30% of older children and…”
Get full text

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study by Yacoub, Abdulraheem, Borate, Uma, Rampal, Raajit K, Ali, Haris, Wang, Eunice, Gerds, Aaron T., Hobbs, Gabriela S., Kremyanskaya, Marina, Winton, Elliott, O'Connell, Casey, Goel, Swati, Oh, Stephen T, Schiller, Gary J., Assad, Albert, Erickson-Viitanen, Sue, Zhou, Feng, Daver, Naval

Get full text